乙醇栓塞硬化治疗动静脉畸形的安全性与有效性:系统评价与Meta分析
该系统评价与Meta分析纳入33项研究共920例肌肉骨骼及软组织动静脉畸形患者,评估乙醇栓塞硬化治疗的安全性与有效性。多次治疗后96%(95%CI:92-98%)患者症状缓解或改善,单次治疗后为25%(95%CI:16-37%);主要不良事件发生率为2%(95%CI:1-3%)。
要点
- 多次治疗后96%患者症状缓解或改善,单次治疗后仅25%。
- 主要不良事件发生率为2%(95%CI:1-3%)。
- 年轻患者结局更有利(SMD=0.35,95%CI:0.02-0.68,p=0.04),手/足病变成功率较低。
核心结论
- 乙醇栓塞硬化治疗动静脉畸形的症状缓解或改善率为96%(95%CI:92-98%),主要不良事件发生率为2%(95%CI:1-3%)。
- 作者认为这些发现支持乙醇栓塞硬化治疗作为动静脉畸形的有效治疗,尤其在年轻患者中,并支持尽可能早期干预。
研究设计与样本
- 系统评价与Meta分析,纳入33项研究、共920例肌肉骨骼及软组织动静脉畸形患者。
- 本综述汇总了多个中心使用的治疗实践,作为临床参考。
诊断标准与关键数值
- 症状缓解或改善:多次治疗后96%(95%CI:92-98%),单次治疗后25%(95%CI:16-37%)。
- 主要不良事件发生率:2%(95%CI:1-3%)。
- 年轻患者结局更有利:SMD=0.35,95%CI:0.02-0.68,p=0.04。
- 结局因解剖部位而异,手/足病变成功率较低。
- 临床分型(Schöbinger II型 vs III型病变)与血管造影分型(Cho-Do II型 vs III型病变)均未显著预测结局。
临床应用与阅片要点
- 作者认为结果支持继续使用乙醇栓塞硬化治疗动静脉畸形,并支持尽可能早期干预。
- 阅片与报告时可关注病变解剖部位,手/足病变的成功率较低。
- 临床Schöbinger分型与血管造影Cho-Do分型未显著预测结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This systematic review and meta-analysis evaluates the safety and effectiveness of ethanol embolosclerotherapy for musculoskeletal and soft tissue arteriovenous malformations. Thirty-three studies comprising 920 patients were included. Symptom resolution or improvement was achieved in 96% (95% CI: 92-98%) of patients after multiple treatments and in 25% (95% CI: 16-37%) following a single treatment. Outcomes were more favourable in younger patients (SMD = 0.35, 95% CI: 0.02-0.68, p = 0.04) and varied by anatomical site, with lower success rates in hand/foot lesions. Major adverse events occurred in 2% (95% CI: 1-3%) of treatments. Clinical (Schöbinger type II vs III lesions) and angiographic (Cho-Do type II vs III lesions) classifications did not significantly predict outcomes. These findings support ethanol embolosclerotherapy as an effective treatment for arteriovenous malformations, particularly in younger patients. KEY POINTS: Question What is the overall effectiveness and safety of ethanol embolosclerotherapy in treating high-flow arteriovenous malformations? Findings Ethanol embolosclerotherapy improved or resolved symptoms in 96% of patients, with major adverse events occurring in only 2% of treatments. Clinical relevance The results provide strong evidence for the continued use of ethanol embolosclerotherapy in the treatment of arteriovenous malformations and support earlier intervention when possible. This review offers clinicians a summary reference of treatment practices used across multiple centres.
引用
- Carroll Downey A, Yakes WF, Park AW, et al. The safety and effectiveness of ethanol embolosclerotherapy in the treatment of arterio-venous malformations: a systematic review and meta-analysis. Eur Radiol. 2026. PMID: 41885924. doi:10.1007/s00330-026-12401-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。